Medication info

Metoglind Tablet 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
You & Life Sciences Co., Ltd.
Appearance
Bright yellow, biconvex, oval-shaped film-coated tablets
Packaging
60 tablets (10 tablets/PTP packaging x 6 packs)
Approval status
Expired

MFDS item code 201907070 · Approved 2019.10.04

This product's status changed to Expired on 2024.10.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined in consideration of each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medicine should start with the same doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
You & Life Sciences Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control
View approved original text

This medication effectively helps control blood sugar levels in adults with type 2 diabetes. It is used as an adjunct to dietary and exercise therapy for blood sugar control and can also be utilized when blood sugar control is difficult with initial monotherapy. Furthermore, it aids in better blood sugar management as a replacement for a combination therapy of linagliptin and metformin or when used in conjunction with insulin. If there is inadequate effectiveness with a combination therapy of metformin and empagliflozin, it can also be administered together to improve blood sugar control. Overall, this medication is used to enhance blood sugar management for diabetes patients at various stages of treatment.

How to take

Adult dose

The dose of this medicine should be determined in consideration of each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medicine should start with the same doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication may cause serious side effects such as lactic acidosis, so caution is required. It should not be administered to individuals allergic to the main ingredients, those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or diabetic pre-coma. Patients with severely decreased kidney function or those in situations where acute changes in kidney function are expected should not use this medication. In cases of severely compromised heart function, acute myocardial infarction, shock, severe infections, etc., it is not safe to administer this medication. Patients with liver dysfunction, severe gastrointestinal disorders, acute alcohol intoxication, or alcoholic syndrome should also avoid using this medication. Pregnant women or women of childbearing potential, as well as nursing mothers, are advised against using this medication. This medication poses a risk of hypoglycemia, so blood sugar levels should be carefully monitored, particularly when used with sulfonylureas or insulin. Due to the risk of lactic acidosis, if dehydration, severe vomiting or diarrhea, acute cardiopulmonary conditions, sepsis, etc., occur, immediate consultation with a physician is necessary. Regular kidney function tests should be conducted to determine the appropriateness of continuing this medication, and it should be discontinued if kidney function worsens. Patients with unstable cardiac function should also use this medication with caution, and it should be temporarily discontinued before and after procedures involving radiographic iodine contrast agents. This medication may induce rare skin disorders such as acute pancreatitis or bullous pemphigoid; if symptoms appear, patients should promptly notify their doctor. Long-term use may result in vitamin B12 deficiency, so regular blood tests should be performed to check if necessary. This medication can interact with various drugs; patients taking other medications must inform their physician or pharmacist and exercise caution. For the elderly, diminished kidney function is common, so appropriate dosage adjustments and regular check-ups are necessary based on kidney function. This medication is not recommended for children or those under 10 years of age as the safety and efficacy have not been established. In case of overdose, serious side effects, such as lactic acidosis, may occur, necessitating immediate hospital treatment. This medication should be stored away from moisture and direct sunlight and kept out of the reach of children.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 110 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • pruritus
  • hypertension
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • drowsiness
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • nasal bleeding
  • hearing loss
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • confusion state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to store it at room temperature between 1°C and 30°C. Following these guidelines will help maintain the medication's effectiveness for an extended period.

Appearance and packaging

Appearance

Bright yellow, biconvex, oval-shaped film-coated tablets

Package unit

60 tablets (10 tablets/PTP packaging x 6 packs)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.